- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Dr. Smith's Diaper Rash Ointment
- CVS Caremark to stop selling tobacco in all store locations
DENVER A cholesterol-lowering drug made by Merck appears to reduce the risk of heart attacks, strokes and cardiac death in patients with chronic kidney disease, according to results of a new study.
Merck said results of a 9,000-patient clinical study showed that Vytorin (ezetimibe and simvastatin) reduced the risks by 16.1% compared with placebo. Results of the study were presented Saturday at the annual meeting of the American Society of Nephrology.
“This is an important study,” Merck Research Labs president Peter Kim said. “Patients with [chronic kidney disease] have a high risk of ischemic vascular disease and increased rates of heart attack, stroke and other cardiovascular events and revascularization procedures.”